Abbott Laboratories, Inc ... Type 2 diabetes using GLP-1 medicines and FreeStyle Libre technology together had greater improvement in their HbA1c (a measurement of a person's average blood ...

Abbott Laboratories was sued on April 3 in Minnesota District Court over alleged employment discrimination. The lawsuit was brought by Schaefer Halleen LLC on behalf of a former company senior ...

Abbott Laboratories engages in the ... Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites.

An analyst from RBC Capital persists with their Outperform rating on Abbott Laboratories, maintaining a target price of $125.

Good morning, and thank you for standing by. Welcome to Abbott's First Quarter 2024 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of ...

Abbott Laboratories ABT is slated to report ... in both the United States and internationally. Across Diabetes Care, Freestyle Libre’s user base surpassed five million globally, with two ...

Abbott expects full-year earnings in the range of $4.55 to $4.70 per share. Abbott shares have decreased roughly 1% since the beginning of the year, while the S&P’s 500 index has risen 6%. The ...

A disappointing earnings season had stocks giving back some of their January gains again Wednesday as Microsoft slumps and Boeing posts a surprise loss. Stock futures lower as U.S. earnings ...

Abbott Laboratories on Wednesday reported first-quarter profit of $1.23 billion ABBOTT PARK, Illinois -- Abbott Laboratories reported a first-quarter profit of $1.23 billion Wednesday. The company ...